As of the latest Form 4 filed May 26, 2026.
What Karyopharm Therapeutics Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 24 most recent filings for KPTI.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | 2026-05-21 | Su Zhen Director | AAward | +15.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | Oliger Christy J. Director | AAward | +15.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | Schor Chen Director | AAward | +15.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | Greene Barry E Director | AAward | +15.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | PAKIANATHAN DEEPIKA Director | AAward | +15.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | BOHLIN GAREN G Director | AAward | +15.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-15 | 2026-05-14 | Poulton Stuart EVP, Chief Development Officer | SSale | −403.00 | $9.50 | $3.83K | No | Form 4 ↗ |
| 2026-05-15 | 2026-05-14 | Rangwala Reshma EVP & Chief Medical Officer | SSale | −408.00 | $9.50 | $3.88K | No | Form 4 ↗ |
| 2026-05-15 | 2026-05-14 | Cheng Sohanya Roshan EVP & Chief Commercial Officer | SSale | −324.00 | $9.50 | $3.08K | No | Form 4 ↗ |
| 2026-05-15 | 2026-05-14 | Abate Kristin Chief Accounting Officer | SSale | −53.00 | $9.50 | $503.50 | No | Form 4 ↗ |
| 2026-05-15 | 2026-05-14 | Paulson Richard A. President and CEO | SSale | −2.20K | $9.50 | $20.9K | No | Form 4 ↗ |
| 2026-05-15 | 2026-05-14 | Mano Michael EVP, CLO&Secretary | SSale | −266.00 | $9.50 | $2.53K | No | Form 4 ↗ |
| 2026-05-15 | 2026-05-13 | Poulton Stuart EVP, Chief Development Officer | AAward | +896.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-15 | 2026-05-13 | Rangwala Reshma EVP & Chief Medical Officer | AAward | +947.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-15 | 2026-05-13 | Cheng Sohanya Roshan EVP & Chief Commercial Officer | AAward | +947.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-15 | 2026-05-13 | Abate Kristin Chief Accounting Officer | AAward | +121.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-15 | 2026-05-13 | Paulson Richard A. President and CEO | AAward | +4.92K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-15 | 2026-05-13 | Mano Michael EVP, CLO&Secretary | AAward | +700.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-22 | 2026-04-21 | Rangwala Reshma EVP & Chief Medical Officer | SSale | −449.00 | $8.94 | $4.01K | No | Form 4 ↗ |
| 2026-02-09 | 2026-02-05 | Paulson Richard A. President and CEO | AAward | +81.1K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-04 | 2026-02-03 | Macomber Lori EVP, CFO & Treasurer | SSale | −1.63K | $6.30 | $10.2K | No | Form 4 ↗ |
| 2026-01-29 | 2026-01-28 | Abate Kristin Chief Accounting Officer | SSale | −50.00 | $7.03 | $351.50 | No | Form 4 ↗ |
| 2026-01-29 | 2026-01-27 | Abate Kristin, Chief Accounting Officer | AAward | +92.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-22 | 2026-01-21 | Abate Kristin Chief Accounting Officer | SSale | −265.00 | $5.96 | $1.58K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also KPTI’s full analysis or the market-wide insider trading feed. The tabs above jump to KPTI’s other SEC data.
Source: SEC Form 4 filings for KPTI, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.